Wednesday, July 8, 2026

Drug profile · INN

aripiprazole

aripiprazole (ABILIFY) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved NMPA: clinical trials Nervous system (N05) N05AX12
US status approved
Patents linked 8
Pipeline programs 13
News articles 0
Drug details — aripiprazole
US status
approved
Class
Nervous system (N05)
Route
INTRAMUSCULAR
Patents
8
Programs
13
Data quality
0.89

Quick answer

aripiprazole (ABILIFY) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN aripiprazole
Brand ABILIFY
Mechanism Serotonin 2a (5-HT2a) receptor antagonist
Target D(2) dopamine receptor
Therapeutic class Nervous system (N05)
Route INTRAMUSCULAR
Formulation TABLET, ORALLY DISINTEGRATING
ATC code N05AX12

Mechanism of action

Serotonin 2a (5-HT2a) receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved
NMPA clinical trials

Pipeline programs

  1. Aripiprazole Phase 3 · Otsuka Beijing Research · Bipolar I
  2. Aripiprazole IM Depot Phase 3 · Otsuka Beijing Research · Schizophrenia
  3. Aripiprazole Phase 2 · BRIGHT MINDS BIOSCIENCES · Substance Abuse
  4. Aripiprazole + Cocaine Phase 2 · BRIGHT MINDS BIOSCIENCES · Cocaine Abuse
  5. CAT-PSY Phase 2 · Telethon Foundation · Substance-Induced Psychosis
  6. Aripiprazole Phase 1 · BRIGHT MINDS BIOSCIENCES · Cocaine-Related Disorders
  7. ARIPIPRAZOLE , RISPERIDONE Approved · Disc Medicine · Autism spectrum disorder
  8. Aripiprazole Approved · Otsuka Beijing Research · Schizophrenia

Related & competitor drugs

  1. brexpiprazole Nervous system (N05)
  2. brivaracetam Nervous system (N03)
  3. bupivacaine Nervous system (N01)
  4. buprenorphine Nervous system (N07)
  5. cabergoline Dopamine D2 receptor agonist
  6. caffeine citrate Nervous system (N06)
  1. US 2019298716

    Aripiprazole Dosing Strategy

    Expires Wed Sep 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. HR P20190642

    ARIPIPRAZOLE PRODRUG COMPOSITIONS

    Expires Thu May 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 2017231981

    COMPOSITIONS OF MULTIPLE ARIPIPRAZOLE PRODRUGS

    Expires Wed Aug 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 2016051546

    CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA

    Expires Wed Feb 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 2016045495

    ARIPIPRAZOLE PRODRUG COMPOSITIONS

    Expires Wed Feb 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 2015265529

    ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS

    Expires Wed Sep 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8865722

    Wet formulations of aripiprazole

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 7504504

    Methods of preparing aripiprazole crystalline forms

    Expires Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is aripiprazole?

aripiprazole (ABILIFY) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for aripiprazole?

ABILIFY is a marketed brand name for aripiprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of aripiprazole?

aripiprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.